Short-acting β2-agonist prescription patterns for asthma management in the SABINA III primary care cohort

David Price* (Corresponding Author), Kerry Hancock, Joseph Doan, Sri Wahyu Taher, Chakaya J Muhwa, Hisham Farouk, Maarten JHI Beekman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)
2 Downloads (Pure)


Short-acting β2-agonist (SABA) prescriptions and associated outcomes were assessed in 1,440 patients with asthma from the SABA use IN Asthma (SABINA) III study treated in primary care. Data on asthma medications were collected and multivariable regression models analysed the association of SABA prescriptions with clinical outcomes. Patients (mean age, 47.9 years) were mostly female (68.6%); 58.3% had uncontrolled/partly controlled asthma and 38.8% experienced ≥1 severe exacerbation (reported in 39% of patients with mild asthma). Overall, 44.9% of patients were prescribed ≥3 SABA canisters
(over-prescription) and 21.5% purchased SABA over-the-counter. Higher SABA prescriptions (vs 1−2 canisters) were associated with significantly decreased odds of having at least partly controlled asthma (6–9 and 10–12 canisters) and an increased incidence rate of severe exacerbations (10–12 and ≥13 canisters). Findings revealed a high disease burden, even in patients with ‘mild’ asthma, emphasizing the need for local primary care guidelines based on international recommendations.
Original languageEnglish
Article number37
Number of pages10
Journalnpj Primary Care Respiratory Medicine
Early online date29 Sept 2022
Publication statusPublished - 29 Sept 2022

Bibliographical note

AstraZeneca funded all the SABINA studies and was involved in designing the study, developing the study protocol, conducting the study and performing the analyses. AstraZeneca was given the opportunity to review the manuscript before submission and funded medical writing support. Writing and editorial support was provided in accordance with Good Publication Practice (GPP3) guidelines ( and fully funded by AstraZeneca.


Dive into the research topics of 'Short-acting β2-agonist prescription patterns for asthma management in the SABINA III primary care cohort'. Together they form a unique fingerprint.

Cite this